NEUROCRINE BIOSCIENCES INC Research and Development Expense
NEUROCRINE BIOSCIENCES INC (NBIX) reported Research and Development Expense of $73.20 million for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-05.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2021-05-05
- NEUROCRINE BIOSCIENCES INC research and development expense for the quarter ending 2021-03-31 was $73.20M, a 25.56% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC research and development expense for the quarter ending 2020-03-31 was $58.30M, a 54.84% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC research and development expense for the quarter ending 2019-06-30 was $61.69M, a 66.78% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC research and development expense for the quarter ending 2019-03-31 was $37.65M, a 23.08% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC research and development expense for fiscal 2018 was $160.52M, a 31.76% increase from fiscal 2017.
- NEUROCRINE BIOSCIENCES INC research and development expense for fiscal 2017 was $121.83M, a 29.20% increase from fiscal 2016.
- NEUROCRINE BIOSCIENCES INC research and development expense for fiscal 2016 was $94.29M, a 15.71% increase from fiscal 2015.
- NEUROCRINE BIOSCIENCES INC research and development expense for fiscal 2015 was $81.49M, a 75.53% increase from fiscal 2014.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2021-03-31 | $73.20M 10-Q · filed 2021-05-05 | |||
| 2020-03-31 | $58.30M 10-Q · filed 2021-05-05 | |||
| 2019-06-30 | $61.69M 10-Q · filed 2019-07-29 | $99.34M 10-Q · filed 2019-07-29 | $138.45M derived: sum of 3 quarters · filed 2019-07-29 | $173.93M derived: sum of 4 quarters · filed 2019-07-29 |
| 2019-03-31 | $37.65M 10-Q · filed 2019-04-29 | $76.76M derived: sum of 2 quarters · filed 2019-04-29 | $112.24M derived: sum of 3 quarters · filed 2019-04-29 | $149.23M derived: sum of 4 quarters · filed 2019-07-29 |
| 2018-12-31 | $39.11M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-08 | $74.59M derived: sum of 2 quarters · filed 2019-02-08 | $111.58M derived: sum of 3 quarters · filed 2019-07-29 | $160.52M 10-K · filed 2019-02-08 |
| 2018-09-30 | $35.48M 10-Q · filed 2018-11-05 | $72.47M derived: sum of 2 quarters · filed 2019-07-29 | $121.42M 10-Q · filed 2018-11-05 | $147.03M derived: sum of 4 quarters · filed 2019-07-29 |
| 2018-06-30 | $36.99M 10-Q · filed 2019-07-29 | $85.94M 10-Q · filed 2019-07-29 | $111.55M derived: sum of 3 quarters · filed 2019-07-29 | $134.01M derived: sum of 4 quarters · filed 2019-07-29 |
| 2018-03-31 | $48.95M 10-Q · filed 2019-04-29 | $74.56M derived: sum of 2 quarters · filed 2019-04-29 | $97.02M derived: sum of 3 quarters · filed 2019-04-29 | $118.89M derived: sum of 4 quarters · filed 2019-04-29 |
| 2017-12-31 | $25.61M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-08 | $48.08M derived: sum of 2 quarters · filed 2019-02-08 | $69.94M derived: sum of 3 quarters · filed 2019-02-08 | $121.83M 10-K · filed 2019-02-08 |
| 2017-09-30 | $22.46M 10-Q · filed 2018-11-05 | $44.33M derived: sum of 2 quarters · filed 2018-11-05 | $96.21M 10-Q · filed 2018-11-05 | $118.80M derived: sum of 4 quarters · filed 2019-02-08 |
| 2017-06-30 | $21.87M 10-Q · filed 2018-07-31 | $73.75M 10-Q · filed 2018-07-31 | $96.33M derived: sum of 3 quarters · filed 2019-02-08 | $117.28M derived: sum of 4 quarters · filed 2019-02-08 |
| 2017-03-31 | $51.88M 10-Q · filed 2018-04-30 | $74.47M derived: sum of 2 quarters · filed 2019-02-08 | $95.41M derived: sum of 3 quarters · filed 2019-02-08 | $122.27M derived: sum of 4 quarters · filed 2019-02-08 |
| 2016-12-31 | $22.58M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-08 | $43.52M derived: sum of 2 quarters · filed 2019-02-08 | $70.39M derived: sum of 3 quarters · filed 2019-02-08 | $94.29M 10-K · filed 2019-02-08 |
| 2016-09-30 | $20.94M 10-Q · filed 2017-11-01 | $47.80M derived: sum of 2 quarters · filed 2017-11-01 | $71.71M 10-Q · filed 2017-11-01 | $93.52M derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-06-30 | $26.86M 10-Q · filed 2017-08-03 | $50.77M 10-Q · filed 2017-08-03 | $72.58M derived: sum of 3 quarters · filed 2018-02-13 | $96.96M derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-03-31 | $23.90M 10-Q · filed 2017-05-09 | $45.71M derived: sum of 2 quarters · filed 2018-02-13 | $70.10M derived: sum of 3 quarters · filed 2018-02-13 | $88.82M derived: sum of 4 quarters · filed 2018-02-13 |
| 2015-12-31 | $21.81M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $46.20M derived: sum of 2 quarters · filed 2018-02-13 | $64.92M derived: sum of 3 quarters · filed 2018-02-13 | $81.49M 10-K · filed 2018-02-13 |
| 2015-09-30 | $24.39M 10-Q · filed 2016-11-02 | $43.11M derived: sum of 2 quarters · filed 2016-11-02 | $59.68M 10-Q · filed 2016-11-02 | $75.18M derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-06-30 | $18.72M 10-Q · filed 2016-08-03 | $35.29M 10-Q · filed 2016-08-03 | $50.79M derived: sum of 3 quarters · filed 2017-02-14 | $62.99M derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-03-31 | $16.57M 10-Q · filed 2016-05-05 | $32.07M derived: sum of 2 quarters · filed 2017-02-14 | $44.27M derived: sum of 3 quarters · filed 2017-02-14 | $54.43M derived: sum of 4 quarters · filed 2017-02-14 |
| 2014-12-31 | $15.50M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-14 | $27.69M derived: sum of 2 quarters · filed 2017-02-14 | $37.85M derived: sum of 3 quarters · filed 2017-02-14 | $46.42M 10-K · filed 2017-02-14 |
| 2014-09-30 | $12.19M 10-Q · filed 2015-10-29 | $22.36M derived: sum of 2 quarters · filed 2015-10-29 | $30.93M 10-Q · filed 2015-10-29 | $39.84M derived: sum of 4 quarters · filed 2016-02-11 |
| 2014-06-30 | $10.16M 10-Q · filed 2015-07-29 | $18.73M 10-Q · filed 2015-07-29 | $27.65M derived: sum of 3 quarters · filed 2016-02-11 | $37.14M derived: sum of 4 quarters · filed 2016-02-11 |
| 2014-03-31 | $8.57M 10-Q · filed 2015-04-30 | $17.49M derived: sum of 2 quarters · filed 2016-02-11 | $26.98M derived: sum of 3 quarters · filed 2016-02-11 | $37.51M derived: sum of 4 quarters · filed 2016-02-11 |
| 2013-12-31 | $8.92M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-11 | $18.41M derived: sum of 2 quarters · filed 2016-02-11 | $28.93M derived: sum of 3 quarters · filed 2016-02-11 | $39.25M 10-K · filed 2016-02-11 |
| 2013-09-30 | $9.49M 10-Q · filed 2014-11-04 | $20.02M derived: sum of 2 quarters · filed 2014-11-04 | $30.33M 10-Q · filed 2014-11-04 | $39.43M derived: sum of 4 quarters · filed 2015-02-09 |
| 2013-06-30 | $10.53M 10-Q · filed 2014-08-06 | $20.84M 10-Q · filed 2014-08-06 | $29.94M derived: sum of 3 quarters · filed 2015-02-09 | $39.80M derived: sum of 4 quarters · filed 2015-02-09 |
| 2013-03-31 | $10.31M 10-Q · filed 2014-05-01 | $19.41M derived: sum of 2 quarters · filed 2015-02-09 | $29.27M derived: sum of 3 quarters · filed 2015-02-09 | $38.09M derived: sum of 4 quarters · filed 2015-02-09 |
| 2012-12-31 | $9.10M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-09 | $18.96M derived: sum of 2 quarters · filed 2015-02-09 | $27.77M derived: sum of 3 quarters · filed 2015-02-09 | $37.16M 10-K · filed 2015-02-09 |
| 2012-09-30 | $9.86M 10-Q · filed 2013-10-29 | $18.68M derived: sum of 2 quarters · filed 2013-10-29 | $28.07M 10-Q · filed 2013-10-29 | $36.07M derived: sum of 4 quarters · filed 2014-02-11 |
| 2012-06-30 | $8.82M 10-Q · filed 2013-07-26 | $18.21M 10-Q · filed 2013-07-26 | $26.21M derived: sum of 3 quarters · filed 2014-02-11 | $33.66M derived: sum of 4 quarters · filed 2014-02-11 |
| 2012-03-31 | $9.39M 10-Q · filed 2013-05-02 | $17.39M derived: sum of 2 quarters · filed 2014-02-11 | $24.85M derived: sum of 3 quarters · filed 2014-02-11 | $33.02M derived: sum of 4 quarters · filed 2014-02-11 |
| 2011-12-31 | $8.00M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-11 | $15.46M derived: sum of 2 quarters · filed 2014-02-11 | $23.63M derived: sum of 3 quarters · filed 2014-02-11 | $30.95M 10-K · filed 2014-02-11 |
| 2011-09-30 | $7.46M 10-Q · filed 2012-10-31 | $15.63M derived: sum of 2 quarters · filed 2012-10-31 | $22.95M 10-Q · filed 2012-10-31 | $31.01M derived: sum of 4 quarters · filed 2013-02-08 |
| 2011-06-30 | $8.18M 10-Q · filed 2012-07-31 | $15.49M 10-Q · filed 2012-07-31 | $23.56M derived: sum of 3 quarters · filed 2013-02-08 | $31.79M derived: sum of 4 quarters · filed 2013-02-08 |
| 2011-03-31 | $7.32M 10-Q · filed 2012-05-02 | $15.38M derived: sum of 2 quarters · filed 2013-02-08 | $23.61M derived: sum of 3 quarters · filed 2013-02-08 | $30.89M derived: sum of 4 quarters · filed 2013-02-08 |
| 2010-12-31 | $8.06M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-08 | $16.29M derived: sum of 2 quarters · filed 2013-02-08 | $23.57M derived: sum of 3 quarters · filed 2013-02-08 | $31.15M 10-K · filed 2013-02-08 |
| 2010-09-30 | $8.23M 10-Q · filed 2011-10-31 | $15.51M derived: sum of 2 quarters · filed 2011-10-31 | $23.09M 10-Q · filed 2011-10-31 | |
| 2010-06-30 | $7.28M 10-Q · filed 2011-07-29 | $14.86M 10-Q · filed 2011-07-29 | ||
| 2009-12-31 | $33.72M 10-K · filed 2012-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |